Multi-parametric Magnetic Resonance Imaging for Prostate Cancer Patients

Prostate Cancer Clinical Trial

Official title:

Pilot Study of Using Multi-parametric Magnetic Resonance Imaging for Organ Delineation and Tumor Response Assessment of Prostate Cancer Patients Being Treated With Radiation Therapy

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT03180398
• Other study ID #: Prostate Imaging 10911
• Status: Terminated
• Phase: N/A
• Start date: October 4, 2017
• Est. completion date: February 15, 2022

Study information

• Verified date: September 2023
• Source: Henry Ford Health System
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a pilot study of implement multi-parametric MR imaging for organ delineation and tumor response assessment of prostate cancer patients being treated with radiation therapy.

Description:

The study aims to generate intraprostatic lesions maps based on imaging, perform the treatment planning to compute the highest feasible simultaneous boosting dose to intraprostatic lesion and characterize longitudinal changes in imaging characteristics.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 9
• Est. completion date: February 15, 2022
• Est. primary completion date: February 15, 2022
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: N/A and older

Eligibility

Inclusion Criteria:

• Histologically confirmed prostate adenocarcinoma

Exclusion Criteria:

• Patients with metal fragments or implanted devices such as pacemakers and aneurysm clips are not eligible for the study considering

Related Conditions & MeSH terms

• Prostate Cancer
• Prostatic Neoplasms

Intervention

Device:
• Multiparametric MRI
MRI will be acquired before, during and after radiation treatment to evaluate treatment response

Locations

Country	Name	City	State
United States	Henry Ford Health System	Detroit	Michigan

Sponsors (1)

Lead Sponsor	Collaborator
Henry Ford Health System

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Detection of Imaging Biomarkers to Localize the Intraprostatic Lesions and Predict Radiation Treatment Response	Identify the radiomics features selected from multimodal MRI to distinguish the dominant lesions from the normal tissues within the prostate. Track the changes of these features with longitudinal MRI scans to identify its correlation with the local control.	2 years
Primary	Tumor Response	Tumor response as measured by an increase in PSA.	2 years